Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV001010427 | SCV001170626 | uncertain significance | Hereditary cancer-predisposing syndrome | 2021-03-19 | criteria provided, single submitter | clinical testing | The p.D409G variant (also known as c.1226A>G), located in coding exon 10 of the CHEK2 gene, results from an A to G substitution at nucleotide position 1226. The aspartic acid at codon 409 is replaced by glycine, an amino acid with similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |